Erratum to “2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk” [Atherosclerosis 290 (2019) 140–205]

Mach, François; Baigent, Colin; Catapano, Alberico L.; Koskinas, Konstantinos C.; Casula, Manuela; Badimón, Lina; Chapman, M. John; Backer, Guy De; Delgado, Victoria; Ference, Brian А.; Graham, Ian; Halliday, Alison; Landmesser, Ulf; Mihaylova, Borislava; Pedersen, Terje R.; Riccardi, Gabriele; Richter, Dimitrios J; Sabatine, Marc S.; Taskinen, Marja‐Riitta; Tokgözoğlu, Lâle; Wiklund, Olov; Nibouche, Djamaleddine; Zelveian, Parounak; Siostrzonek, Peter; Najafov, Ruslan; Borne, Philippe van de; Pojskić, Belma; Postadzhiyan, Arman; Kypris, Lambros; Špinar, Jindřich; Larsen, Mogens Lytken; Eldin, Hesham Salah; Viigimaa, Margus; Strandberg, Timo; Ferrières, Jean; Agladze, Rusudan; Laufs, Ulrich; Rallidis, Lοukianos S.; Bajnok, László; Gudjonsson, Thorarinn; Maher, Vincent; Henkin, Yaakov; Gulizia, Michele Massimo; Bajraktari, Gani; Kerimkulova, Alina; Latkovskis, Gustavs; Hamoui, Omar; Šlapikas, Rimvydas; Visser, Laurent; Dingli, Philip; Ivanov, Victoria; Bošković, Aneta; Nazzi, M.; Visseren, Frank L J; Mitevska, Irena; Retterstøl, Kjetil; Jankowski, Piotr; Fontes‐Carvalho, Ricardo; Gaiță, Dan; Ezhov, Marat; Foscoli, Marina; Pella, Daniel; Fras, Zlatko; Isla, Leopoldo Pérez de; Hagström, Emil; Lehmann, Roger; Abid, Leïla; Özdoğan, Öner; Mitchenko, O.; Patel, Riyaz; Windecker, Stephan; Aboyans, Victor; Collet, Jean‐Philippe; Dean, Veronica; Fitzsimons, Donna; Gale, Chris P; Grobbee, Diederick E.; Halvorsen, Sigrun; Hindricks, Gerhard; Iung, Bernard; Jüni, Peter; Katus, Hugo A.; Leclercq, Christophe; Lettino, Maddalena; Lewis, Basil S.; Merkely, Béla; Mueller, Christian; Petersen, Steffen E.; Petronio, Anna Sonia; Roffi, Marco; Shlyakhto, Evgeny; Simpson, Iain; Sousa-Uva, Miguel; Touyz, Rhian M.

doi:10.1016/j.atherosclerosis.2019.11.020

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first Adult Treatment Panel for National Cholesterol Education Program (NCEP-ATP I) recommended in 1988 low-density cholesterol (LDL-C) target level of <130 mg/dL for primary prevention of cardiovascular disease [7]. Subsequent guidelines gradually lowered the target LDL-C levels and further defined the risk groups of vascular events until in 2019 the European Society of Cardiology recommended an LDL-C target of ≤55 mg/dL and a ≥50% LDL-C reduction from baseline in very-high-risk patients [8], a recommendation ranked as class I level of evidence A for secondary prevention and as class I level of evidence B in primary prevention, mentioning that older people should be treated in the same way as younger patients (class I, level of evidence A). For stroke as well, the European Stroke Organization (ESO) endorsed aggressive lipid-lowering therapy [9] recommending standard treatment with atorvastatin 80 mg/day in secondary prevention after an ischemic stroke or a transient ischemic attack (Grade A).…”

Section: Introductionmentioning

confidence: 99%

Cognition, Statins, and Cholesterol in Elderly Ischemic Stroke Patients: A Neurologist’s Perspective

Jurcău

Simion

2021

Medicina

View full text Add to dashboard Cite

Background and Objectives: The efficacy of hydroxy methyl glutaryl-coenzyme A reductase inhibitors (statins) in reducing the incidence of cardiovascular events pushed the target LDL-cholesterol (LDL-C) levels lower and lower in successive guidelines despite signals regarding potential cognitive side effects. We evaluated the relationship between cognitive impairment and LDL-C levels in elderly ischemic stroke patients. Materials and Methods: 29 ischemic stroke patients aged 65 and above with LDL-C levels ≤70 mg/dL, classified according to the TOAST criteria, underwent detailed neuropsychological testing comprising the MMSE test, Montreal Cognitive Assessment (MoCA) and Addenbrooke’s Cognitive Evaluation (ACE-III) test. Their performances were compared to those of 29 age-matched ischemic stroke patients with LDL-Cl levels >71 mg/dL. Results: The MMSE test failed to detect significant cognitive differences between the two groups. The MoCA and ACE-III tests detected impairments in visuo-spatial/executive function, attention, and recall/memory in patients with low LDL-C. A stepwise linear regression model of the ACE-III total scores revealed that LDL-cholesterol levels could contribute to 13.8% of the detected cognitive dysfunction, second in importance only to age, which contributed to 38.8% of the detected impairment. Conclusions: Physicians should be cautious when prescribing statins to elderly people. Hydrophilic ones may be preferred in cognitively impaired patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Cognition, Statins, and Cholesterol in Elderly Ischemic Stroke Patients: A Neurologist’s Perspective

Jurcău

Simion

2021

Medicina

View full text Add to dashboard Cite

show abstract

Non-HDL or LDL cholesterol in heterozygous familial hypercholesterolaemia: findings of the Simon Broome Register

Soran

Durrington

Capps

et al. 2020

Current Opinion in Lipidology

View full text Add to dashboard Cite

Purpose of review:The role of non-high-density lipoprotein cholesterol (non-HDL-C) in the identification and management of lipid disorders is not clearly defined, although UK guidelines recommend its wider use in assessing the need for lipidlowering therapy and as a treatment target. Recent findings: We examined the implications of the use of non-HDL-C as opposed to LDL-C in 253 people with hypercholesterolaemia before treatment and 573 after treatment in whom fasting total serum cholesterol, HDL-C and LDL-C had been recorded and the diagnosis of heterozygous familial hypercholesterolemia (heFH) was investigated by genetic testing. The difference and the limits of agreement between non-HDL-C and LDL-C calculated using the Friedewald formula were assessed in those with and without heFH-causing mutations. Summary: There were 147 mutation positive and 106 mutation-negative pretreatment participants and 395 mutation positive and 178 mutation-negative patients receiving treatment. The difference between non-HDL-C and LDL-C pre-treatment in mutation-positive people (mean LDL-C 7.73mmol/l) was 0.67 mmol/L (95% CI 0.62─0.73) and post-treatment (mean LDL-C 4.71mmol/l) was 0.62 mmol/l (95% CI 0.59─0.65) with wide limits of agreement of -0.02─1.37 mmol/L and 0.07─1.18 mmol/L respectively. Among patients with heterozygous familial hypercholesterolaemia, use of estimated LDL-C derived from non-HDL-C in place of calculated LDL-C may result in diagnostic misclassification and difficulty in assessing the true reduction in LDL-C with treatment, because of the wide inter-individual limits of agreement around the mean difference between non-HDL-C and LDL-C.

show abstract

Epicardial adipose tissue is associated with increased systolic pulmonary artery pressure in patients with chronic obstructive pulmonary disease

Kalaycıoğlu

Çetin

Çinier

et al. 2020

Clinical Respiratory J

View full text Add to dashboard Cite

Objectives Pulmonary hypertension (PHT) is one of the essential predictors of mortality in chronic obstructive pulmonary disease (COPD). It is thought that PHT is due to vasoconstriction secondary to hypoxia caused by airway obstruction in COPD patients; however, loss of capillary bed with emphysema, inflammation, and endothelial dysfunction may also play a role in the development of PHT. Epicardial adipose tissue (EAT) has a role as a metabolically active endocrine organ and secretes various proinflammatory cytokines. We hypothesized that EAT thickness in COPD patients might be associated with the systolic pulmonary arterial pressure (PAPs) level, and we aimed to test it. Methods The present study included 129 consecutive patients with the diagnosis of COPD. All patients underwent transthoracic echocardiographic evaluation. The relationship between PAPs and EAT thickness was evaluated. Results Positive correlations with PAPs were reported with age, EAT, white blood cell (WBC) and GOLD grade score (range 0.197‐0.275, P values 0.026 to 0.002), negative correlations with body‐mass index (BMI), hyperlipidemia, FEV1 (% predicted) and pO2 (range −0.216 to −0.340, P values .014 to <.001). In stepwise linear regression analysis, BMI (P = .003), EAT (P = .002), WBC (P = .001), and FEV1 (% predicted) (P = .010), were independently associated with PAPs. Conclusion EAT thickness in COPD patients with preserved left ventricular systolic function is associated with increased PAPs, and this association is independent of the parameters indicating the severity of COPD.

show abstract

Erratum to “2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk” [Atherosclerosis 290 (2019) 140–205]

Cited by 4 publications

References 0 publications

Cognition, Statins, and Cholesterol in Elderly Ischemic Stroke Patients: A Neurologist’s Perspective

Cognition, Statins, and Cholesterol in Elderly Ischemic Stroke Patients: A Neurologist’s Perspective

Non-HDL or LDL cholesterol in heterozygous familial hypercholesterolaemia: findings of the Simon Broome Register

Epicardial adipose tissue is associated with increased systolic pulmonary artery pressure in patients with chronic obstructive pulmonary disease

Contact Info

Product

Resources

About